Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to ...
Incyte reported strong Q3 revenue growth, mainly driven by Jakafi and Opzelura, with a 24% increase year-over-year. Find out ...
On Friday, Incyte Corp (INCY) stock saw a modest uptick, ending the day at $83.38 which represents a slight increase of $1.04 or 1.26% from the prior close of $82.34. The stock opened at $82.59 and ...
Fierce Pharma Asia—AstraZeneca's China fallout; Pfizer's $1B plan in China; Incyte-Sun JAK dispute
AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and ...
Incyte filed a lawsuit to try to block the launch of Leqselvi, claiming that the drug infringed a US patent (No. 9,662,335) ...
On Tuesday, Incyte Corporation (NASDAQ:INCY) reported third-quarter revenue of $1.14 billion, up 24% year over year and ...
Incyte delivered robust third-quarter revenue growth, surpassing expectations, despite increased operational costs.
On Tuesday, Incyte Corporation (NASDAQ:INCY) reported third-quarter revenue of $1.14 billion, up 24% year over year, beating ...
Shares of Incyte (NASDAQ:INCY) jumped 8% after the company reported better-than-expected Q3 revenue and raised sales guidance ...
12don MSN
Incyte (NASDAQ:INCY) is scheduled to announce Q3 earnings results on Tuesday, October 29th, before market open. The consensus ...
Incyte (INCY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Andrew Berens ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback